×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Curis Announces Additional Data from TakeAim Leukemia Study
PR Newswire
PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available,...
1 week ago
Curis Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo Movies Canada
Curis ( NASDAQ:CRIS ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.83m (down 7.0% from 3Q 2021). Net...
16 hours ago
Little Village: The Next Big Thing In Detroit
Forbes
Focused on art, architecture, the landscape, and access to the waterfront, Little Village is anchored by the Shepherd, the former Good...
1 week ago
Curis: Q1 Earnings Snapshot
The Washington Post
LEXINGTON, Mass. — LEXINGTON, Mass. — Curis Inc. (CRIS) on Tuesday reported a loss of $11.9 million in its first quarter.
2 weeks ago
Curis to Present Updated Data from the TakeAim Leukemia Study
Nasdaq
Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor,...
2 weeks ago
Curis shares rise as analysts see 'the next Pharmacyclics'
MarketWatch
Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target.
6 months ago
Curis (NASDAQ:CRIS) Given “Buy” Rating at Truist Financial
Defense World
Read Curis (NASDAQ:CRIS) Given “Buy” Rating at Truist Financial at Defense World.
3 days ago
Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study
Yahoo Life UK
The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies.
2 days ago
Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
Yahoo News UK
Investors focused on the Medical space have likely heard of Curis (CRIS), but is the stock performing well in comparison to the rest of its...
4 days ago
Curis Provides Fourth Quarter 2023 Business Update
PR Newswire
LEXINGTON, Mass., Feb. 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA...
3 months ago